Market Closed

HALO
Halozyme Therapeutics
$ 100.27
-0.40%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

Halozyme Therapeutics News

Latest Halozyme Therapeutics Stock News & HALO Headlines

Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
3 days ago | zacks.com
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
4 days ago | zacks.com
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
4 days ago | zacks.com
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
8 days ago | zacks.com
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
8 days ago | zacks.com
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
8 days ago | prnewswire.com
What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call
9 days ago | marketbeat.com
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics
9 days ago | zacks.com
Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates
9 days ago | zacks.com
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
10 days ago | zacks.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

HALO
Halozyme Therapeutics
$ 100.27
-0.40%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago